Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma

被引：0

作者：

Waldschmidt, Johannes M. ^{[1
,2
,3
,4
]}

Sotudeh, Noori ^{[1
,2
,3
]}

Arora, Sankalp ^{[5
,6
]}

Vijaykumar, Tushara ^{[1
,2
]}

Anand, Praveen ^{[1
,2
,3
]}

Stuart, Hannah ^{[1
,2
,3
]}

Frede, Julia ^{[1
,2
,3
]}

Campbell, Tim ^{[7
]}

Kaiser, Shari M. ^{[7
]}

Zheng, Xirong ^{[7
]}

Munshi, Nikhil C. ^{[1
,2
]}

Anderson, Kenneth C. ^{[1
,2
]}

Einsele, Hermann ^{[4
]}

Yee, Andrew J. ^{[5
]}

Knoechel, Birgit ^{[2
,3
,8
]}

Lohr, Jens G. ^{[1
,3
]}

Raje, Noopur S. ^{[2
,3
,5
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[2] Harvard Med Sch, Boston, MA USA

[3] Broad Inst MIT & Harvard, Cambridge, MA USA

[4] Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany

[5] Massachussetts Gen Hosp, Ctr Multiple Myeloma, Dept Hematol Oncol, Boston, MA USA

[6] MD ANDERSON CANC CTR, DEPT HEMATOL, HOUSTON, TX USA

[7] Bristol Myers Squibb, Princeton, NJ USA

[8] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA

来源：

BLOOD ADVANCES | 2025年 / 9卷 / 05期

关键词：

THERAPY;

D O I：

10.1182/bloodadvances.2024015285

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1132 / 1136

页数：5

共 50 条

[21] Sequential Administration of Selinexor and CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Gill, Sarvarinder Kaur
Biran, Noa
Phull, Pooja
Vesole, David H.
Siegel, David S.
Parmar, Harsh
BLOOD, 2023, 142
[22] Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma
Feng, Deming
Sun, Jian
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2020, 92 (02)
[23] Fair Allocation of Scarce CAR T-Cell Therapies for Relapsed/Refractory Multiple Myeloma
Derman, Benjamin A.
Parker, William F.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (08): : 687 - 688
[24] CAR T-cell therapy for lymphoma and multiple myeloma
Kochenderfer, James N.
CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
[25] Toxicity of CAR T-Cell Therapy for Multiple Myeloma
Afrough, Aimaz
Abraham, Pearl Rajan
Turer, Laura
Kaur, Gurbakhash
Sannareddy, Aishwarya
Hansen, Doris K.
Anderson, Larry D.
ACTA HAEMATOLOGICA, 2024,
[26] Multitargeted CAR T-cell therapy in multiple myeloma
Adaniya, Sandra Susanibar
Garfall, Alfred L.
LANCET HAEMATOLOGY, 2019, 6 (10): : E494 - E495
[27] APRIL CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Phase I Clinical Trial
Li, Wenxiao
Hu, Yongxian
Zhang, Mingming
Lai, Xinyi
Zhao, Mengyu
Fu, Shan
Hong, Ruimin
Chang, Alex H.
Huang, He
BLOOD, 2024, 144 : 7229 - 7229
[28] Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China
Wu, Weijia
Ding, Shuyi
Zhang, Mingming
Zhou, Yuping
Sun, Xueshan
Zhao, Zixuan
Yang, Yi
Hu, Yongxian
Dong, Hengjin
JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 701 - 709
[29] Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma
Dancy, Ehren
Garfall, Alfred L.
Cohen, Adam D.
Fraietta, Joseph A.
Davis, Megan
Levine, Bruce L.
Siegel, Don L.
Stadtmauer, Edward A.
Vogl, Dan T.
Waxman, Adam
Rapoport, Aaron P.
Milone, Michael C.
June, Carl H.
Melenhorst, J. Joseph
BLOOD, 2018, 132
[30] A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy
Banerjee, Rahul
Lynch, Ryan C.
Wu, Qian
Simon, Sylvain
Ujjani, Chaitra S.
Till, Brian G.
Wuliji, Natalie
Gausman, Daria
Dizon, Joshua
Kwok, Mary L.
Lee, Sarah S.
Silbermann, Rebecca
Medvedova, Eva
Maloney, David G.
Ramos, Jorge Daniel
Shadman, Mazyar
Gauthier, Jordan
Turtle, Cameron J.
Gopal, Ajay K.
Green, Damian J.
Riddell, Stanley R.
Cowan, Andrew J.
BLOOD, 2023, 142

← 1 2 3 4 5 →